Raphael Pharmaceutical entered an AI transformation and growth Partnership with AIcreatesAI carrying an annual managed-services fee of $180,000, payable monthly at $15,000. Investors should note that unpaid invoices can become deferred obligations, while any digital token platform would require board approval and pay AIcreatesAI 2% of net profits.

Key Highlights

  • Monthly payments under the agreement are set at $15,000, subject to deferred-payment provisions.
  • Either party may terminate the agreement for an uncured material breach after written notice.
  • Raphael Pharmaceutical’s agreement with AIcreatesAI carries a $180,000 annual managed-services fee.

Raphael Pharmaceutical Inc. (OTC: RAPH) has engaged AIcreatesAI as its managed artificial intelligence transformation and growth partner under an agreement carrying a $180,000 annual fee. The arrangement took effect on July 30, 2026, and begins with an annual term covering commercialization, communications, product and growth operations.

$180,000 Annual AI Services Agreement

The $180,000 fee is payable through monthly installments of $15,000. Services remain subject to Raphael Pharmaceutical’s approval, applicable law and the agreement’s compliance controls. When funds are temporarily unavailable, unpaid invoices automatically become deferred payment obligations.